Upgrade to SI Premium - Free Trial

Merck (MRK) announces EC Approves its KEYTRUDA in Combination with Inlyta as First-Line Treatment for Patients with Advanced RCC

September 4, 2019 6:51 AM
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles